BioMedReports.com is a website for healthcare investors and traders, which features a discussion forum, stock research reports, news feeds, videos, stock commentaries, and calendars for upcoming FDA new product decisions and clinical trial results.
Editor reviews are provided by professional editors who evaluate a blog based on the following criteria: Frequency of Updates, Relevance of Content, Site Design, and Writing Style.
BioCryst Pharmaceuticals (NASDAQ:BCRX) said a late-stage study testing the intravenous form of its experimental influenza drug peramivir showed the drug was not inferior to another flu drug, Tamiflu, sending its shares up 50 percent.
Analysts are expecting a favorable decision from U.S. health regulators on the additional use of Spectrum Pharmaceuticals' (NASDAQ:SPPI) cancer drug Zevalin as a first-line therapy for non-Hodgkin's lymphoma (NHL), which will give a much-needed boost...
